Select Date
- >
Loading available days...
Available Slots:
Overview
Dr. Shefali Sardana is a highly accomplished Medical Oncologist with over 18 years of clinical experience, known for integrating advanced science with compassionate, patient-centred care. She specialises in Gastrointestinal and Hepato-Pancreato-Biliary cancers, with additional expertise in genitourinary, gynecological and breast cancers. Skilled in immunotherapy, targeted therapy and precision oncology, she brings deep experience in managing complex solid organ malignancies through a multidisciplinary approach.
An active clinical researcher and Principal Investigator in international trials, Dr. Sardana has presented at global forums including ASCO-GI and has contributed to national guidelines and medical textbooks. Her leadership roles in oncology societies and international conference platforms reflect her academic and clinical credibility.
Her association significantly strengthens Athenaa’s medical oncology programme by bringing advanced systemic therapy expertise, research-driven treatment strategies and a holistic healing philosophy. With her blend of scientific excellence and empathetic care, she enhances Athenaa’s commitment to delivering personalised, world-class cancer treatment focused not only on survival, but on dignity and quality of life.
Experience
- Treated 15,000+ cancer patients across early-stage, locally advanced, and metastatic settings over 18+ years of oncology practice.
- Administered and supervised 40,000+ cycles of chemotherapy, immunotherapy, and targeted therapy with precision-driven treatment protocols.
- Led and contributed as Principal Investigator / Co-Investigator in multiple national and international clinical trials, advancing access to novel therapies.
- Presented research at prestigious global platforms including ASCO-GI, contributing Indian real-world data to international oncology discourse.
- Authored peer-reviewed publications, national guideline contributions, and textbook chapters, including work on molecular oncology and gut microbiome in cancer.
- Held key leadership roles including Executive Committee Member, Oncology Forum and Former Convener, Delhi Breast Oncology Group
Memberships
- Executive Committee Member, Oncology Forum (India)
- Former Convener, Delhi Breast Oncology Group (A Unit of Oncology Forum)
- Member, American Society of Clinical Oncology (ASCO)
- Member, European Society for Medical Oncology (ESMO)
- Member, Indian Society of Medical & Paediatric Oncology (ISMPO)
- Member, Young Oncology Group of India (YOGI)
- Member, Indian Medical Association (IMA)
Awards
Certifications :
- Fellowship, International Preceptorship in Colorectal Cancers, Charité University Hospital, Berlin, Germany (2024)
- Fellowship, International Preceptorship in Kidney Cancers, Singapore (2019)
Research and Publication
- Clinical trials: PI in phase 1/1b, multicenter randomised trial of RP12146, PARP-I in patients with BRCA1/2 mutated mCRPC
- Clinical trials: Co-PI in three current ongoing trials: "Add Aspirin," Capitello, and Destiny
- Conference organization: Organized the international Max Gyn-Onc Conference in Sept. 2021
- Conference organization: Organized the International Women Breast Cancer Congress (WBCC) in Dec. 2020
- Specialized training: Completed a preceptorship in colorectal cancers at the Charité Hospital in Berlin, Germany
- Administrative roles: Ex-Convener for the Delhi Breast Oncology Group (a unit of Oncology Forum) from 2023–25
- Administrative roles: Current Executive Committee Member of the Oncology Forum
- Publications & Research: Cardiovascular research: ECG changes in acute cerebrovascular accident (CVA): a prospective study
- Publications & Research: Book chapters: Authored a chapter on "Gut Microbiome and Cancer" for the Indian Association of Physicians Annual Book 2024
- Publications & Research: Clinical guidelines: Localised Rectal Cancer: Indian Consensus and Guidelines (published in the Indian Journal of Medical and Paediatric Oncology)
- Publications & Research: Recent abstracts (ASCO-GI 2025): Real-world evidence of a tissue-free ctDNA-based minimal residual disease (MRD) testing in colorectal cancer (CRC): Insights from an Indian cohort
- Publications & Research: Recent abstracts (ASCO-GI 2025): Immune checkpoint inhibitors (ICIs) in deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-colorectal cancers: Real-world Indian data and the use of alternative dosing (Abstract #347)
Special Interests
- Gastrointestinal & Hepatopancreatobiliary Oncology
- Precision Oncology, Immunotherapy & Targeted Therapies
- Genitourinary & Gynecological Cancers
- Comprehensive Breast Cancer Management
- Clinical Research & Evidence-Based Oncology
- Holistic, Patient-Centred Cancer Care
Best Hospital Near me Chennai